oligonucleotides for next generation sequencing research and clinical diagnostics

14
John Havens, PhD VP, Business Development Integrated DNA Technologies AMP Workshop 2014 Oligonucleotides for Next Generation Sequencing Research and Clinical Diagnostics

Upload: integrated-dna-technologies

Post on 15-Jul-2015

687 views

Category:

Science


2 download

TRANSCRIPT

Page 1: Oligonucleotides for Next Generation Sequencing Research and Clinical Diagnostics

John Havens, PhD

VP, Business Development

Integrated DNA Technologies

AMP Workshop 2014

Oligonucleotides for Next Generation Sequencing

Research and Clinical Diagnostics

Page 2: Oligonucleotides for Next Generation Sequencing Research and Clinical Diagnostics

2

INTEGRATED DNA TECHNOLOGIES

IDT Hybridization Enrichment Panels

• Stocked panels• Acute Myeloid Leukemia

• 264 genes, recurrently mutated in 200 AML patients, 1.4 Mb target space• Developed with TCGA, Wash U Genome Institute, Tim Ley• Published in NEJM 368, 2059 (2013)

• Pan-Cancer• 127 genes, from 12 cancers analyzed in 3281 tumors, 800 kb target space• Developed with TCGA, Wash U Genome Institute, Li Ding• Published in Nature 502, 333 (2013)

• Inherited Diseases

• 4503 genes, from Human Genetic Mutation Database

• Developed with Emory Genetics Laboratory, Madhuri Hegde

• Custom panels

• Supplements to stocked panels—fast, inexpensive

• Completely custom sets—fast, inexpensive if more than a few samples

• Wide range in target space from 700 bases to 2 Mb

Page 3: Oligonucleotides for Next Generation Sequencing Research and Clinical Diagnostics

3

INTEGRATED DNA TECHNOLOGIES

xGen® Predesigned Gene Capture Pools

• Pools of xGen® Lockdown®

probes targeting all exons of designated genes

• Available as individual pools for each gene or in one tube combining pools for all genes

• Shipped in solution and ready to use

Page 4: Oligonucleotides for Next Generation Sequencing Research and Clinical Diagnostics

4

INTEGRATED DNA TECHNOLOGIES

Acute Myeloid Leukemia Targeted Enrichment

• IDT AML set covering 264 genes spiked into NimbleGen exome

• ~100% coverage of the AML target space

• Coverage depths for AML set ~500X, allowing clone detection down to ~5%

The Genome Institute, Washington University

Page 5: Oligonucleotides for Next Generation Sequencing Research and Clinical Diagnostics

5

INTEGRATED DNA TECHNOLOGIES

High-Fidelity Individual Oligo Synthesis

• Per-step coupling efficiency has a big influence on full-length yield

• 99.6% coupling efficiency enables oligos of 200 bases

• Full-length desalted yields:• 60mers: 79%

• 120mers: 62%

• 200mers: 45%

• 5′ chemical biotinylation improves effective purity

Page 6: Oligonucleotides for Next Generation Sequencing Research and Clinical Diagnostics

6

INTEGRATED DNA TECHNOLOGIES

ESI Mass Spectroscopy for Quality Control

BioGCGGCGAGCGGAGATCCGGGGCCTGCGCTGCGCACTCGAGCCTGGCGGGCCGGCACGGTGCGGGCCATGAGCGGGGCGGTGCCCCAGGACCTAGCGGTGAGTGGCGGCCGAGTCGGGCAC

ESI-MS trace of an

xGen® Lockdown® probe

with 78% GC content

Page 7: Oligonucleotides for Next Generation Sequencing Research and Clinical Diagnostics

7

INTEGRATED DNA TECHNOLOGIES

Synthesis Failures

• 120mer DNA probes with 5′ biotin

• Each probe requires ~5000 steps to manufacture

• ~116,000 probes for inherited diseases panel of ~4500 genes

• 62% full-length product

• Most truncation products capped and not biotinylated

• QC failures remade and included in pool if they pass

0

5,000

10,000

15,000

20,000

25,000

30,000

35,000

40,000

0%

2%

4%

6%

8%

10%

12%

Nu

mb

er

of

Cap

ture

Pro

be

s

Firs

t-P

ass

Fail

Rat

e

Probe GC Content

Number of Probes First Pass Fail Rate

Page 8: Oligonucleotides for Next Generation Sequencing Research and Clinical Diagnostics

8

INTEGRATED DNA TECHNOLOGIES

Enhanced Hybridization Probes for NGS Target Enrichment

• Individually synthesized

• Individually QCed by ESI MS

• Individually normalized

• Chemically biotinylated

• Failures resynthesized

• Normally 120mers, but range can be60–200mers

• Processed robotically

• Available as 21 CFR Part 820 (GMP)

Page 9: Oligonucleotides for Next Generation Sequencing Research and Clinical Diagnostics

9

INTEGRATED DNA TECHNOLOGIES

High-Efficiency Universal Blockers

• Blockers remove adapter participation in hybridization enrichment

• Universal blockers contain inosines that hybridize to barcodes and proprietary modifications for improved affinity

• On-target percentages can show 60% improvement

• This translates to lower sequencing costs, particularly for multiplexed samples

Foundation Medicine

Page 10: Oligonucleotides for Next Generation Sequencing Research and Clinical Diagnostics

10

INTEGRATED DNA TECHNOLOGIES

Barcoded Adapters for Library Preparation

Custom adapters available:• More barcodes

• Dual indexing to minimize cross contamination

• Degenerate barcodes for molecular indexing

• TruGrade™ processing

The Genome Institute, Washington University

Page 11: Oligonucleotides for Next Generation Sequencing Research and Clinical Diagnostics

11

INTEGRATED DNA TECHNOLOGIES

TruGrade™ Analysis from the Sanger Institute

• “With HPLC (Company A) or PAGE (Company B) purification, approximately 0.56% and 0.34% mapped to missing barcodes.”

• “With TruGrade this was dramatically reduced to just 0.03%.”

Mike Quail

Page 12: Oligonucleotides for Next Generation Sequencing Research and Clinical Diagnostics

12

INTEGRATED DNA TECHNOLOGIES

gBlocks® Gene Fragments as NGS Standards

• dsDNA of 125–2000 bp

• Copy number variants

• Troubleshooting library preparation

• Rare-allele detection

• Sequencing accuracy as a function of sequence composition

Carlson, et al., Nature Comm. 2013.

Page 13: Oligonucleotides for Next Generation Sequencing Research and Clinical Diagnostics

13

INTEGRATED DNA TECHNOLOGIES

Summary of IDT NGS Products

• Individually synthesized, QCed, normalized hybridization probes offer:• Complete, uniform capture of the target space

• 4-hour hybridization time

• Insensitivity to targets with minor mismatches

• Capability for SNV, indel, CNV, LOH, and translocation detection

• 21 CFR Part 820 manufacture for clinical research and diagnostics

• Stocked or custom panels

• Universal blockers improve on-target performance for multiplexed samples

• Custom adapters available to improve sequencing performance

Page 14: Oligonucleotides for Next Generation Sequencing Research and Clinical Diagnostics

14

INTEGRATED DNA TECHNOLOGIES

Additional Resources• xGen® Lockdown® Panels

www.idtdna.com/xGen

• Videoswww.youtube.com/idtdnabio

• Improving NGS Target Capture

• Expanding Your Research Capabilities Using Targeted NGS

• IDT DECODED newsletter articleswww.idtdna.com/DECODED

• Core Concepts: Target Enrichment Facilitates Focused Next Generation Sequencing

• Your Research: Insertion Site Detection and Targeted RNA Capture Using Next Generation

Sequencing (Cofactor Genomics, St. Louis, MO)

• Your Research: Next Generation Sequencing in the Clinic: A Perspective from Dr Elaine Mardis

(Washington University, St. Louis, MO)

• Your Research: Target Enrichment Identifies Mutations that Confer Fitness Effects (University of

Texas, Austin, TX)